Cargando…
Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)
INTRODUCTION: Recent cardiovascular outcomes trials have demonstrated that glucagon-like peptide 1 receptor agonist (GLP-1RA) decreases the incidence of major adverse cardiovascular events (MACEs) in individuals with type 2 diabetes mellitus (T2DM). Polyethylene glycol loxenatide (PEG-Loxe) is a onc...
Autores principales: | Xie, Yun, Kuang, Jian, Li, Quanmin, Hong, Tianpei, Ji, Linong, Kong, Yuanyuan, Duan, Yale, Chen, Liming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193081/ https://www.ncbi.nlm.nih.gov/pubmed/37192802 http://dx.doi.org/10.1136/bmjopen-2022-069080 |
Ejemplares similares
-
Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial
por: Cai, Hongyu, et al.
Publicado: (2023) -
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
por: Wang, Jianwen, et al.
Publicado: (2019) -
Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice
por: Wu, Yuting, et al.
Publicado: (2021) -
Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial
por: Zhang, Shuo, et al.
Publicado: (2023) -
Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice
por: Zhang, Yu, et al.
Publicado: (2021)